$
7.610
-0.24(-3.057%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.180
Open
8.470
VWAP
8.42
Vol
2.41M
Mkt Cap
16.15M
Low
7.290
Amount
20.26M
EV/EBITDA(TTM)
--
Total Shares
9.40M
EV
13.28M
EV/OCF(TTM)
--
P/S(TTM)
--
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Show More
2 Analyst Rating
up Image
83.97% Upside
Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up Image
83.97% Upside
Current: 7.610
sliders
Low
14.00
Averages
14.00
High
14.00
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
2025-05-19
Reason
D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.
Boral Capital
D. Boral
Buy
downgrade
$29 -> $17
2025-05-13
Reason
D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$14
2025-03-26
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-03-24
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-02-27
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-02-19
Reason

Valuation Metrics

The current forward P/E ratio for Imunon Inc (IMNN.O) is -0.65, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess Imunon Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.49
Current PE
-0.65
Overvalued PE
0.13
Undervalued PE
-3.12

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
49.88
Current PS
0.00
Overvalued PS
123.33
Undervalued PS
-23.58

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-17.28%
-4.15M
Operating Profit
FY2025Q1
YoY :
-16.78%
-4.10M
Net Income after Tax
FY2025Q1
YoY :
-46.15%
-0.28
EPS - Diluted
FY2025Q1
YoY :
-47.22%
-3.11M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
79.7K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

IMNN News & Events

Events Timeline

2025-07-30 (ET)
2025-07-30
08:09:24
Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001
select
2025-07-28 (ET)
2025-07-28
08:16:20
Imunon board approves 15% stock dividend
select
2025-07-23 (ET)
2025-07-23
08:13:19
Imunon announces 1-for-15 reverse split ratio
select
Sign Up For More Events

News

9.0
07-30Benzinga
PinnedIMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?
7.0
07-15Newsfilter
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
9.0
06-17Newsfilter
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
Sign Up For More News

FAQ

arrow icon

What is Imunon Inc (IMNN) stock price today?

The current price of IMNN is 7.61 USD — it has decreased -3.06 % in the last trading day.

arrow icon

What is Imunon Inc (IMNN)'s business?

arrow icon

What is the price predicton of IMNN Stock?

arrow icon

What is Imunon Inc (IMNN)'s revenue for the last quarter?

arrow icon

What is Imunon Inc (IMNN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Imunon Inc (IMNN)'s fundamentals?

arrow icon

How many employees does Imunon Inc (IMNN). have?

arrow icon

What is Imunon Inc (IMNN) market cap?